Ohcanbohtosat - Vivek Subbiah

Aiddostahte ozu
  1. 1
    Chronic Lung Disease after Premature Birth

    Chronic Lung Disease after Premature Birth Dahkki Vivek Subbiah

    Almmustuhtton 2008
    Viečča ollesdeavstta
    Carta
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    The next generation of evidence-based medicine

    The next generation of evidence-based medicine Dahkki Vivek Subbiah

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Tissue-agnostic cancer therapies: promise, reality, and the path forward

    Tissue-agnostic cancer therapies: promise, reality, and the path forward Dahkki Vivek Subbiah

    Almmustuhtton 2025
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Challenging Standard-of-Care Paradigms in the Precision Oncology Era

    Challenging Standard-of-Care Paradigms in the Precision Oncology Era Dahkki Vivek Subbiah, Razelle Kurzrock

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Managing Cancer Care during the COVID-19 Pandemic and Beyond

    Managing Cancer Care during the COVID-19 Pandemic and Beyond Dahkki Omar Alhalabi, Vivek Subbiah

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i>

    Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> Dahkki Vivek Subbiah, Razelle Kurzrock

    Almmustuhtton 2023
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Tumor-agnostic drug development in dMMR/MSI-H solid tumors

    Tumor-agnostic drug development in dMMR/MSI-H solid tumors Dahkki Deepak Bhamidipati, Vivek Subbiah

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Clinical development and management of adverse events associated with FGFR inhibitors

    Clinical development and management of adverse events associated with FGFR inhibitors Dahkki Vivek Subbiah, Srđan Verstovšek

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Advances in Targeting RET-Dependent Cancers

    Advances in Targeting RET-Dependent Cancers Dahkki Vivek Subbiah, Gilbert J. Cote

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy

    Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy Dahkki Mohamed A. Gouda, Vivek Subbiah

    Almmustuhtton 2023
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors

    Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors Dahkki Mohamed A. Gouda, Vivek Subbiah

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers

    Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers Dahkki Mohamed A. Gouda, Vivek Subbiah

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Clinical Development of BRAF plus MEK Inhibitor Combinations

    Clinical Development of BRAF plus MEK Inhibitor Combinations Dahkki Vivek Subbiah, Christina S. Baik, John M. Kirkwood

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm

    From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm Dahkki Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives

    Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives Dahkki Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

    Almmustuhtton 2017
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

    The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians Dahkki Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Editorial
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers

    State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers Dahkki Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    The abscopal effect in patients with cancer receiving immunotherapy

    The abscopal effect in patients with cancer receiving immunotherapy Dahkki Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies?

    From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? Dahkki Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

    Almmustuhtton 2025
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  20. 20
    The emerging role of PI3K inhibitors for solid tumour treatment and beyond

    The emerging role of PI3K inhibitors for solid tumour treatment and beyond Dahkki Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

    Almmustuhtton 2023
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: